{"id":"recaticimab-and-statin","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection risk (IL-6 inhibition)"},{"rate":null,"effect":"Muscle-related adverse events (statin)"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL5095381","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Recaticimab blocks interleukin-6 (IL-6), a key pro-inflammatory cytokine, thereby reducing systemic inflammation. When combined with a statin (HMG-CoA reductase inhibitor), the regimen addresses both inflammatory and lipid-driven cardiovascular pathology, potentially reducing atherosclerotic progression and cardiovascular events.","oneSentence":"Recaticimab is a monoclonal antibody that inhibits IL-6 signaling to reduce inflammation, combined with a statin to manage lipid levels and provide cardiovascular protection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:36:58.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular disease with elevated inflammatory markers"}]},"trialDetails":[{"nctId":"NCT06902740","phase":"PHASE4","title":"PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque","enrollment":300},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Recaticimab and Statin","genericName":"Recaticimab and Statin","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recaticimab is a monoclonal antibody that inhibits IL-6 signaling to reduce inflammation, combined with a statin to manage lipid levels and provide cardiovascular protection. Used for Cardiovascular disease with elevated inflammatory markers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}